Addington, J, Addington, D, Abidi, S, et al. (2017) Canadian treatment guidelines for individuals at clinical high risk of psychosis. Canadian Journal of Psychiatry, 62: 656–66.
Amminger, GP, Schäfer, MR, Papageorgiou, K, et al. (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry, 67: 146–54.
Amminger, G, Schäfer, M, Schlögelhofer, M, et al. (2015) Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nature Communications, 6: 7934.
Bhattacharyya, S, Wilson, R, Appia-Kusi, E, et al. (2018) Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry, 75: 1107–17.
Boggs, DL, Surti, T, Gupta, A, et al. (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology, 235: 1923–32.
Cannon, TD, Yu, C, Addington, J, et al. (2016) An individualized risk calculator for research in prodromal psychosis. American Journal of Psychiatry, 173: 980–8.
Cornblatt, BA, Lencz, T, Smith, CW, et al. (2007) Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. Journal of Clinical Psychiatry, 68: 546–57.
Davies, C, Cipriani, A, Ioannidis, J, et al. (2018a) Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry, 17: 196–209.
Davies, C, Radua, J, Cipriani, A, et al. (2018b) Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. Frontiers in Psychiatry, 9: 187.
Devoe, DJ, Farris, MS, Townes, P, et al. (2019) Attenuated psychotic symptom interventions in youth at risk of psychosis: a systematic review and meta-analysis. Early Intervention in Psychiatry, 13: 3–17.
Dong, C, Haschimoto, K (2015) Early intervention for psychosis with N-methyl-d-aspartate receptor modulators. Clinical Psychopharmacology and Neuroscience, 13: 328–9.
Emsley, R (2009) Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia. Evidence-Based Mental Health, 12(2): 43.
Fusar-Poli, P, Borgwardt, S, Bechdolf, A, et al. (2013a) The psychosis high-risk state: a comprehensive state-of-the-art review. Archives of General Psychiatry, 70(1): 107–20.
Fusar-Poli, P, Bechdolf, A, Taylor, MJ, et al. (2013b) At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophrenia Bulletin, 39: 923–32.
Fusar-Poli, P, Cappucciati, M, Rutigliano, G, et al. (2015a) At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry, 14: 322–32.
Fusar-Poli, P, Frascarelli, M, Valmaggia, L, et al. (2015b) Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychological Medicine, 45: 1327–39.
Fusar-Poli, P, Cappucciati, M, Rutigliano, G, et al. (2016a) Towards a standard psychometric diagnostic interview for subjects at ultra high risk of psychosis: CAARMS versus SIPS. Psychiatry Journal, 2016: 1–11.
Fusar-Poli, P, Schultze-Lutter, F (2016b) Predicting the onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning. Evidence-Based Mental Health, 19: 10–5.
Fusar-Poli, P, Díaz-Caneja, CM, Patel, R, et al. (2016c) Services for people at high risk improve outcomes in patients with first episode psychosis. Acta Psychiatrica Scandinavica, 133: 76–85.
Fusar-Poli, P, Rutigliano, G, Stahl, D, et al. (2017a) Development and validation of a clinically based risk calculator for the transdiagnostic prediction of psychosis. JAMA Psychiatry, 74: 493–500.
Fusar-Poli, P, McGorry, PD, Kane, JM (2017b) Improving outcomes of first-episode psychosis: an overview. World Psychiatry, 16: 251–65.
Gage, SH, Hickman, M, Zammit, S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biological Psychiatry, 79: 549–56.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390: 1211–59.
Häfner, H, Maurer, K, Löffler, W, et al. (1998) The ABC schizophrenia study: a preliminary overview of the results. Social Psychiatry and Psychiatric Epidemiology, 33(8): 380–6.
Iseger, TA, Bossong, MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 162: 153–61.
Jaaskelainen, E, Juola, P, Hirvonen, N, et al. (2013) A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin, 39: 1296–306.
Khoury, JM, Neves, MdCLd, Roque, MAV, et al. (2017) Is there a role for cannabidiol in psychiatry? World Journal of Biological Psychiatry, Feb 20: doi: 10.1080/15622975.2017.1285049 [Epub ahead of print].
Klosterkötter, J, Ruhrmann, S, Schultze-Lutter, F, et al. (2005) The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry, 4: 161–7.
Klosterkötter, J, Schultze-Lutter, F, Bechdolf, A, et al. (2011) Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry, 10: 165–74.
Koutsouleris, N, Kambeitz-Ilankovic, L, Ruhrmann, S, et al. (2018) Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recentonset depression: a multimodal, multisite machine learning analysis. JAMA Psychiatry, 75: 1156–72.
Leweke, FM, Piomelli, D, Pahlisch, F, et al. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2: e94.
Lin, A, Wood, SJ, Nelson, B, et al. (2015) Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. American Journal of Psychiatry, 172: 249–58.
McGlashan, T, Walsch, B, Woods, S (2010) The Psychosis-Risk Syndrome. Handbook for Diagnosis and Follow-up. Oxford University Press.
McGorry, PD, Nelson, B, Markulev, C, et al. (2017) Effect of ω−3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry, 74: 19–27.
McGuire, P, Robson, P, Cubala, WJ, et al. (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. American Journal of Psychiatry, 175: 225–31.
Mechelli, A, Lin, A, Wood, S, et al. (2017) Using clinical information to make individualized prognostic predictions in people at ultra high risk for psychosis. Schizophrenia Research, 184: 32–8.
Michel, C, Ruhrmann, S, Schimmelmann, BG, et al. (2018) Course of clinical high-risk states for psychosis beyond conversion. European Archives of Psychiatry and Clinical Neuroscience, 268: 39–48.
Murray, RM, Quigley, H, Quattrone, D, et al. (2016) Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry, 15: 195–204.
National Institute for Health and Care Excellence (2014) Psychosis and Schizophrenia in Adults: Treatment and Management (NICE Clinical Guideline CG178). NICE.
Nelson, B, Yuen, HP, Lin, A, et al. (2016) Further examination of the reducing transition rate in ultra high risk for psychosis samples: the possible role of earlier intervention. Schizophrenia Research, 174: 43–9.
Nelson, B, Amminger, G, Yuen, H, et al. (2018) NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders – medium-term follow-up and clinical course. NPJ Schizophrenia, 4: 11.
Oliver, D, Davies, C, Crossland, G, et al. (2018) Can we reduce the duration of untreated psychosis? A systematic review and meta-analysis of controlled interventional studies. Schizophrenia Bulletin, 44: 1362–72.
Polari, A, Lavoie, S, Yuen, HP, et al. (2018) Clinical trajectories in the ultra-high risk for psychosis population. Schizophrenia Research, Feb 18: doi: 10.1016/j.schres.2018.01.022 [Epub ahead of print].
Ruhrmann, S, Schultze-Lutter, F, Salokangas, RK, et al. (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Archives of General Psychiatry, 67: 241–51.
Schimmelmann, BG, Conus, P, Cotton, S, et al. (2007) Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophrenia Research, 95: 1–8.
Schimmelmann, BG, Walger, P, Schultze-Lutter, F (2013) The significance of at-risk symptoms for psychosis in children and adolescents. Canadian Journal of Psychiatry, 58: 32–40.
Schmidt, SJ, Schultze-Lutter, F, Schimmelmann, BG, et al. (2015) EPA guidance on the early intervention in clinical high risk states of psychoses. European Psychiatry, 30: 388–404.
Schmidt, A, Cappucciati, M, Radua, J, et al. (2017) Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. Schizophrenia bulletin, 43: 375–88.
Schultze-Lutter, F, Addington, J, Ruhrmann, S, et al. (2007) Schizophrenia Proneness Instrument, Adult Version. Giovanni Fioriti Editore.
Schultze-Lutter, F, Ruhrmann, S (2008) Früherkennung und Frühbehandlung von Psychosen. UNI-MED.
Schultze-Lutter, F, Koch, E (2010) Schizophrenia Proneness Instrument, Child & Youth Version (SPI-CY). Giovanni Fioriti Editore.
Schultze-Lutter, F, Michel, C, Schmidt, SJ, et al. (2015) EPA guidance on the early detection of clinical high risk states of psychoses. European Psychiatry, 30: 405–16.
Schultze-Lutter, F, Michel, C, Ruhrmann, S, et al. (2017) Prevalence and clinical relevance of interview-assessed psychosis-risk symptoms in the young adult community. Psychological Medicine, 48: 1167–78.
Simon, AE, Borgwardt, S, Riecher-Rössler, A, et al. (2013) Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Research, 209: 266–72.
Studerus, E, Ramyead, A, Riecher-Rössler, A (2017) Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting. Psychological Medicine, 47: 1163–78.
van der Gaag, M, Smit, F, Bechdolf, A, et al. (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophrenia Research, 149: 56–62.
van Os, J, Guloksuz, S (2017) A critique of the “ultra-high risk” and “transition” paradigm. World Psychiatry, 16: 200–6.
Woods, SW, Kantrowitz, JT, Javitt, DC (2014) NMDAR-based treatments for patients at clinical high risk for psychosis. Biological Psychiatry, 1: 11S.
Yung, AR, Yung, AR, Pan Yuen, H, et al. (2005) Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Australian and New Zealand Journal of Psychiatry, 39: 964–71.